Kyowa Hakko Kogyo (PK)【KYKOF】銘柄情報

Kyowa Hakko Kogyo (PK) (KYKOF) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

14.425

( - )

買値

13.90

売値

16.43

出来高

0.00 日の範囲 0.00

12.42 52 週間の範囲 18.00

時価総額

7.551B

前日終値

14.425

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

US$ 1,499,638

発行済株式数

523,486,836

配当利回り

62 (2.94%)

PER

16.44

1 株当たり利益 (EPS)

139.27

歳入

510.57B

純利益

72.91B

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia w... Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodularis; KK8398 infigratinib, which is in Phase III clinical trial for the treatment of achondroplasia; OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4951 tivozanib, which is in Phase II clinical trial for the treatment of diabetic macular edema and neovascular age-related macular degeneration; and OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A. In addition, the company is involved in the development of KK2260 and KK2269, which are both in Phase I clinical trials for the treatment of advanced or metastatic solid tumors; KK2845, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; KK3910, which is in Phase I clinical trial for the treatment of essential hypertension; KK4277, which is in Phase I clinical trial for the treatment of systemic/cutaneous lupus erythematosus; and KK8123, which is in Phase I clinical trial for the treatment of X-linked hypophosphatemia. It has a partnership with La Jolla Institute for Immunology for research in disease areas; AstraZeneca for severe asthma treatment; and AMGEN for therapeutic drugs development. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in July 2019. Kyowa Kirin Co., Ltd. was incorporated in 1949 and is headquartered in Chiyoda, Japan. The company operates as a subsidiary of Kirin Holdings Company, Limited. 詳細を表示

セクター

Healthcare

業界

Pharmaceuticals

ウェブサイト

www.kyowakirin.com

本社

Chiyoda, Japan

設立

2026

Kyowa Hakko Kogyo (PK) is listed in the Healthcare sector of the その他OTC with ticker KYKOF. The last closing price for Kyowa Hakko Kogyo (PK) was US$14.43. Over the last year, Kyowa Hakko Kogyo (PK) shares have traded in a share price range of US$ 12.42 to US$ 18.00.

Kyowa Hakko Kogyo (PK) currently has 523,486,836 shares in issue. The market capitalisation of Kyowa Hakko Kogyo (PK) is US$7.55 billion. Kyowa Hakko Kogyo (PK) has a price to earnings ratio (PE ratio) of 16.44.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	14.425	15.074222	14.425	18558	14.45648506	CS
12	-0.625	-4.15282392027	15.05	15.074222	14.425	6336	14.47053608	CS
26	-2.165	-13.0500301386	16.59	18	12.42	2890	14.84450682	CS
52	-2.715	-15.8401400233	17.14	18	12.42	1944	15.25766054	CS
156	-5.138	-26.2638654603	19.563	22.214	12.316	2037	16.78752101	CS
260	-21.6443	-60.0075410391	36.0693	37.332	12.316	2247	20.76673937	CS